ASX Penny Stocks To Watch In August 2026

The Australian market is experiencing some fluctuations, with the S&P/ASX 200 recently dipping by 0.23%, while Wall Street continues to show strength with record highs. In this context, penny stocks remain a compelling area of interest for investors seeking opportunities in smaller or less-established companies. Despite their vintage name, these stocks can offer significant value when they possess strong financials and growth potential, making them worth considering for those looking to explore new investment avenues.

Here we highlight a subset of our preferred stocks from the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Delta Lithium Limited focuses on the exploration and development of lithium properties in Western Australia, with a market capitalization of A$129.13 million.

Operations: There are no reported revenue segments for the company.

Market Cap: A$129.13M

Delta Lithium Limited, with a market cap of A$129.13 million, is pre-revenue and unprofitable, making it challenging to compare its growth to the broader industry. Its short-term assets of A$59.8 million comfortably cover both short-term and long-term liabilities, indicating financial stability despite its lack of revenue. The company remains debt-free and has not experienced significant shareholder dilution recently. Although earnings are forecasted to decline by an average of 8.5% annually over the next three years, Delta Lithium maintains a cash runway exceeding three years based on current free cash flow trends.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: LTR Pharma Limited is a clinical-stage pharmaceutical company focused on developing an intranasal spray for treating erectile dysfunction in Australia, with a market cap of A$94.52 million.

Operations: The company’s revenue is derived entirely from its Medical Research and Development segment, totaling A$1.13 million.

Market Cap: A$94.52M

LTR Pharma Limited, with a market cap of A$94.52 million, is pre-revenue and focuses on developing an intranasal spray for erectile dysfunction. The company is debt-free and its short-term assets of A$26.3 million exceed its short-term liabilities significantly, suggesting financial solidity despite the absence of substantial revenue streams. However, LTR Pharma’s share price has been highly volatile recently, and it remains unprofitable with a negative return on equity of -33.31%. The management team and board are relatively inexperienced, but the firm maintains a cash runway exceeding three years based on current free cash flow trends.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Rimfire Pacific Mining Limited is an Australian company focused on the exploration and evaluation of critical mineral deposits, with a market cap of A$41.60 million.

Operations: Rimfire Pacific Mining Limited has not reported any revenue segments.

Market Cap: A$41.6M

Rimfire Pacific Mining Limited, with a market cap of A$41.60 million, is pre-revenue and focuses on mineral exploration. The company remains debt-free, with short-term assets of A$1.8 million surpassing its short-term liabilities of A$1.2 million, indicating a manageable financial position despite the lack of significant revenue streams. Recent executive changes include David Hutton transitioning to Technical Director and Bronwyn Barnes being appointed as Executive Chair, potentially strengthening strategic direction and resource development efforts. Rimfire’s share price has been highly volatile recently; however, it has raised an additional A$2.3 million through a follow-on equity offering to support operations amidst financial challenges.

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com